"Embrace precision medicine and tumor-agnostic therapy"
By Eo, Yun-Ho | translator Alice Kang
21.04.29 17:54:14
가나다라
0
[Interview] Kyong-Hwa Park, Professor of Oncology and Hematology at Korea University Anam Hospital
“Succeeded in initiating 20 clinical trials for ‘Lazertinib’ etc. through the K-Master project ”
A separate track needs to be prepared by regulatory authorities for personalized medicines like Rozlytrek etc.
▲박경화 교수
“It’s our turn to adjust to tumor-agnostic therapies."
HER2, ALK, EGFR, ROS1. These are keywords that frequently catch our eye in news about anticancer drugs.
Times have changed. Effective treatment for patients these days depends on the genetic mutation of each patient. With treatments that target personalized genes continue being introduced, the development of precision medicine has heralded the shift in the field of anticancer treatment from ‘disease-based' to ‘gene-based' treatment.
For example, Roche’s Neurotrophic tyrosine receptor kinase (NTRK) ‘Rozlytrek (entrectinib)’ has already been approved as a tumor-agnostic anticancer drug in Korea. Also, MSD�
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)